TMC114/ritonavir — Competitive Intelligence Brief

TMC114/ritonavir (TMC114/ritonavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

marketed HIV protease inhibitor HIV protease Infectious Disease Small molecule

Target snapshot

TMC114/ritonavir (TMC114/ritonavir) — Janssen-Cilag Ltd.. TMC114 (darunavir) is a protease inhibitor that blocks HIV protease, preventing viral replication when boosted with ritonavir.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TMC114/ritonavir TARGET	TMC114/ritonavir	Janssen-Cilag Ltd.	marketed	HIV protease inhibitor	HIV protease
raltegravir and atazanavir and ritonavir	raltegravir and atazanavir and ritonavir	Giovanni Di Perri	marketed	Antiretroviral combination therapy (INSTI + PI + booster)	HIV integrase, HIV protease
Different HAART regimens	Different HAART regimens	Danish HIV Research Group	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition)
Atazanavir-Ritonavir/ Stavidine / Lamivudine	Atazanavir-Ritonavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Lopinavir/ritonavir and ritonavir	Lopinavir/ritonavir and ritonavir	University of Miami	marketed	HIV protease inhibitor	HIV protease
Raltegravir, lopinavir, ritonavir	Raltegravir, lopinavir, ritonavir	Allina Health System	marketed	Antiretroviral combination therapy (integrase inhibitor + protease inhibitors)	HIV integrase, HIV protease
atazanavir/raltegravir	atazanavir/raltegravir	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + integrase inhibitor)	HIV protease and HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

1. Bristol-Myers Squibb · 5 drugs in this class
2. ViiV Healthcare · 3 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Drugs for Neglected Diseases · 2 drugs in this class
5. Germans Trias i Pujol Hospital · 2 drugs in this class
6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
7. DualityBio Inc. · 1 drug in this class
8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
9. Far East Bio-Tec Co., Ltd · 1 drug in this class
10. Community Research Initiative of New England · 1 drug in this class